Inseego Corp (INSG) Q4 2025 Earnings Call Transcript

Why It Matters

The coding shift threatens physician reimbursement, directly affecting Inspire’s procedure volume and future revenue, while the company’s growth trajectory hinges on navigating these reimbursement challenges and expanding its digital ecosystem.

Key Takeaways

• Q4 revenue up 12% to $269M, FY up 14% to $912M.
• 2026 revenue guidance $950M‑$1B, 4‑10% growth range.
• Coding shift to CPT 64582‑52 may cut fees 10‑50%.
• Inspire 5 training complete; >90% centers ready.
• WISER prior auth causing Medicare delays in six states.

Pulse Analysis

Inspire Medical Systems’ latest earnings release underscores a robust top‑line performance, with fourth‑quarter revenue climbing 12% and full‑year sales surpassing $900 million. The growth was propelled by a blend of expanding existing implant centers and adding new locations, reflecting the company’s continued market penetration in the sleep‑apnea therapy space. However, the financial outlook for 2026 is now framed by a broader guidance range, as management grapples with the imminent coding transition for the Inspire 5 system. This uncertainty introduces a potential 10%‑50% cut in professional fees, a factor that could dampen physician adoption rates and compress margins if not mitigated.

The coding controversy centers on the shift to CPT 64582 with a -52 modifier, a change that could significantly lower reimbursement for the procedure. Inspire is actively engaging payers, physician societies, and regulatory bodies to argue for a reduced fee impact, citing the higher surgical complexity of the Inspire 5 implant. Simultaneously, the company is advancing long‑term strategies, including the development of a dedicated CPT code and expanding its digital platform, SleepSync, which now supports 3‑Tesla MRI compatibility and a new prior‑authorization feature aimed at smoothing patient access.

Beyond reimbursement, operational initiatives are reshaping Inspire’s commercial model. The firm has completed physician training for Inspire 5, achieved over 90% center readiness, and is optimizing its territory management by moving toward a 1:1 ratio of territory managers to field clinical reps. While the WISER prior‑authorization program has introduced Medicare delays in six pilot states, Inspire’s proactive support for centers and ongoing advocacy work aim to mitigate these disruptions. Collectively, these actions position the company to sustain growth, improve patient outcomes, and navigate the evolving regulatory landscape.